Plasma lipoprotein(a) concentration predicts future coronary and cardiovascular events in patients with stable coronary heart disease

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 33, Issue 12, 2013, Pages 2902-2908

  Nestel, Paul J ^a   Barnes, Elizabeth H ^b   Tonkin, Andrew M ^c   Simes, John ^b   Fournier, Marion ^b   White, Harvey D ^d   Colquhoun, David M ^e   Blankenberg, Stefan ^f   Sullivan, David R ^g  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d AUCKLAND CITY HOSPITAL   (New Zealand)

^e UNIVERSITY OF QUEENSLAND   (Australia)

^f UNIVERSITY HEART CENTER HAMBURG   (Germany)

^g ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

Cardiovascular diseases; Coronary disease; Lipoprotein(a); Pravastatin

Indexed keywords

APOLIPOPROTEIN B; C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PRAVASTATIN; TRIACYLGLYCEROL;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HOSPITALIZATION; HUMAN; HUMAN TISSUE; HYPERTENSION; ISCHEMIC HEART DISEASE; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; TRANSLUMINAL CORONARY ANGIOPLASTY; TRIACYLGLYCEROL BLOOD LEVEL; UNSTABLE ANGINA PECTORIS;

CARDIOVASCULAR DISEASES; CORONARY DISEASE; LIPOPROTEIN(A); PRAVASTATIN;

AGED; ANGINA, UNSTABLE; AUSTRALIA; BIOLOGICAL MARKERS; CORONARY DISEASE; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPOPROTEIN(A); MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NEW ZEALAND; PRAVASTATIN; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; UP-REGULATION;

EID: 84888203269     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.113.302479     Document Type: Article

References (33)

1. Ariyo AA, Thach C, Tracy R; Cardiovascular Health Study Investigators. Lp(a) lipoprotein, vascular disease, and mortality in the elderly. N Engl J Med. 2003;349:2108-2115
2. Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA. 2009;301:2331-2339
3. Kamstrup PR, Benn M, Tybjaerg-Hansen A, Nordestgaard BG. Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: The Copenhagen City Heart Study. Circulation. 2008;117:176-184
4. Kamstrup PR, Tybjærg-Hansen A, Nordestgaard BG. Extreme lipoprotein(a) levels and improved cardiovascular risk prediction. J Am Coll Cardiol. 2013;61:1146-1156
5. Danesh J, Collins R, Peto R. Lipoprotein(a) and coronary heart disease. Meta-Analysis of prospective studies. Circulation. 2000;102:1082-1085
6. Jones SR, Blumenthal RS. Lipoprotein measurement and determining risk of myocardial infarction. JAMA. 2009;302:1645; author reply 1645-1646
7. Virani SS, Brautbar A, Davis BC, Nambi V, Hoogeveen RC, Sharrett AR, Coresh J, Mosley TH, Morrisett JD, Catellier DJ, Folsom AR, Boerwinkle E, Ballantyne CM. Associations between lipoprotein(a) levels and cardiovascular outcomes in black and white subjects: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 2012;125:241-249
8. Erqou S, Thompson A, Di Angelantonio E, Saleheen D, Kaptoge S, Marcovina S, Danesh J. Apolipoprotein(a) isoforms and the risk of vascular disease: Systematic review of 40 studies involving 58,000 participants. J Am Coll Cardiol. 2010;55:2160-2167
9. Lamon-Fava S, Marcovina SM, Albers JJ, Kennedy H, Deluca C, White CC, Cupples LA, McNamara JR, Seman LJ, Bongard V, Schaefer EJ. Lipoprotein(a) levels, apo(a) isoform size, and coronary heart disease risk in the Framingham Offspring Study. J Lipid Res. 2011;52:1181-1187
10. Von Eckardstein, Schulte H, Cullen P, Assmann GA. Lipoprotein(a) further increases the risk of coronary events in men with high global cardiovascular risk. J Am Coll Cardiol. 2001;37:434-439
11. Nicholls SJ, Tang WH, Scoffone H, Brennan DM, Hartiala J, Allayee H, Hazen SL. Lipoprotein(a) levels and long-Term cardiovascular risk in the contemporary era of statin therapy. J Lipid Res. 2010;51:3055-3061
12. Nordestgaard BG, Chapman MJ, Ray K, et al; European Atherosclerosis Society Consensus Panel. Lipoprotein(a) as a cardiovascular risk factor: Current status. Eur Heart J. 2010;31:2844-2853
13. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med. 1998;339:1349-1357
14. Marschner IC, Colquhoun D, Simes RJ, Glasziou P, Harris P, Singh BB, Friedlander D, White H, Thompson P, Tonkin A; Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study. Long-Term risk stratification for survivors of acute coronary syndromes. Results from the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study. LIPID Study Investigators. J Am Coll Cardiol. 2001;38:56-63
15. Suk Danik J, Rifai N, Buring JE, Ridker PM. Lipoprotein(a), measured with an assay independent of apolipoprotein(a) isoform size, and risk of future cardiovascular events among initially healthy women. JAMA. 2006;296:1363-1370
16. Di Angelantonio E, Gao P, Pennells Let al; Emerging Risk Factor Collaboration. Lipid-related markers and cardiovascular disease prediction. JAMA. 2012;307:2499-2506
17. Wild SH, Fortmann SP, Marcovina SM. A prospective case-control study of lipoprotein(a) levels and apo(a) size and risk of coronary heart disease in Stanford Five-City Project participants. Arterioscler Thromb Vasc Biol. 1997;17:239-245
18. Mora S, Kamstrup PR, Rifai N, Nordestgaard BG, Buring JE, Ridker PM. Lipoprotein(a) and risk of type 2 diabetes. Clin Chem. 2010;56:1252-1260
19. Deb A, Caplice NM. Lipoprotein(a): New insights into mechanisms of atherogenesis and thrombosis. Clin Cardiol. 2004;27:258-264
20. Spence JD, Koschinsky M. Mechanisms of lipoprotein(a) pathogenicity: Prothrombotic, proatherosclerotic, or both? Arterioscler Thromb Vasc Biol. 2012;32:1550-1551
21. Kamstrup PR, Tybjærg-Hansen A, Nordestgaard BG. Genetic evidence that lipoprotein(a) associates with atherosclerotic stenosis rather than venous thrombosis. Arterioscler Thromb Vasc Biol. 2012;32:1732-1741
22. Helgadottir A, Gretarsdottir S, Thorleifsson G, et al. Apolipoprotein(a) genetic sequence variants associated with systemic atherosclerosis and coronary atherosclerotic burden but not with venous thromboembolism. J Am Coll Cardiol. 2012;60:722-729
23. Li Y, Luke MM, Shiffman D, Devlin JJ. Genetic variants in the apolipoprotein(a) gene and coronary heart disease. Circ Cardiovasc Genet. 2011;4:565-573
24. Kiechl S, Willeit J, Mayr M, Viehweider B, Oberhollenzer M, Kronenberg F, Wiedermann CJ, Oberthaler S, Xu Q, Witztum JL, Tsimikas S. Oxidized phospholipids, lipoprotein(a), lipoprotein-Associated phospholipase A2 activity, and 10-year cardiovascular outcomes: Prospective results from the Bruneck study. Arterioscler Thromb Vasc Biol. 2007;27:1788-1795
25. Tsimikas S, Brilakis ES, Miller ER, McConnell JP, Lennon RJ, Kornman KS, Witztum JL, Berger PB. Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N Engl J Med. 2005;353:46-57
26. Nenseter MS, Lindvig HW, Ueland T, Langslet G, Ose L, Holven KB, Retterstøl K. Lipoprotein(a) levels in coronary heart disease-susceptible and-resistant patients with familial hypercholesterolemia. Atherosclerosis. 2011;216:426-432
27. Nielsen LB, Juul K, Nordestgaard BG. Increased degradation of lipoprotein(a) in atherosclerotic compared with nonlesioned aortic intima-inner media of rabbits: In vivo evidence that lipoprotein(a) may contribute to foam cell formation. Arterioscler Thromb Vasc Biol. 1998;18:641-649
28. Tsironis LD, Katsouras CS, Lourida ES, Mitsios JV, Goudevenos J, Elisaf M, Tselepis AD. Reduced PAF-Acetylhydrolase activity associated with Lp(a) in patients with coronary artery disease. Atherosclerosis. 2004;177:193-201
29. Tsimikas S, Hall JL. Lipoprotein(a) as a potential causal genetic risk factor of cardiovascular disease: A rationale for increased efforts to understand its pathophysiology and develop targeted therapies. J Am Coll Cardiol. 2012;60:716-721
30. Thanassoulis G, Campbell CY, Owens DS, et al; CHARGE Extracoronary Calcium Working Group. Genetic associations with valvular calcification and aortic stenosis. N Engl J Med. 2013;368:503-512
31. Visser ME, Witztum JL, Stroes ES, Kastelein JJ. Antisense oligonucleotides for the treatment of dyslipidaemia. Eur Heart J. 2012;33:1451-1458
32. Bloomfield D, Carlson GL, Sapre A, Tribble D, McKenney JM, Littlejohn TW 3rd, Sisk CM, Mitchel Y, Pasternak RC. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients. Am Heart J. 2009;157:352-360.e2
33. Kronenberg F, Trenkwalder E, Dieplinger H, Utermann G. Lipoprotein(a) in stored plasma samples and the ravages of time. Why epidemiological studies might fail. Arterioscler Thromb Vasc Biol. 1996;16:1568-1572